1. Home
  2. BTMD vs ENTX Comparison

BTMD vs ENTX Comparison

Compare BTMD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biote Corp.

BTMD

Biote Corp.

HOLD

Current Price

$2.22

Market Cap

64.4M

Sector

Health Care

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.19

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTMD
ENTX
Founded
2012
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.4M
62.6M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
BTMD
ENTX
Price
$2.22
$1.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$2.83
$10.00
AVG Volume (30 Days)
303.3K
162.6K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
722.22
N/A
EPS
0.74
0.25
Revenue
$192,219,000.00
$42,000.00
Revenue This Year
$2.03
N/A
Revenue Next Year
$6.58
N/A
P/E Ratio
$3.03
$4.88
Revenue Growth
N/A
N/A
52 Week Low
$1.27
$0.91
52 Week High
$4.75
$3.22

Technical Indicators

Market Signals
Indicator
BTMD
ENTX
Relative Strength Index (RSI) 69.22 47.32
Support Level $2.02 $0.96
Resistance Level $2.79 $1.61
Average True Range (ATR) 0.15 0.12
MACD 0.08 0.01
Stochastic Oscillator 85.39 32.14

Price Performance

Historical Comparison
BTMD
ENTX

About BTMD Biote Corp.

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: